AML and chemotherapy. A study recently co-authored by Oncologica
The ability to assess which patients with acute myeloid leukemia (AML) will derive benefit from chemotherapy is a challenge using current technologies. Oncologica has recently co-authored a study in which we show that analysis of the proliferative state of leukemic tumour cells exploiting the evolutionary conserved proteins that replicate a cell’s DNA can be used to predict outcome and enables us to identify those patients most likely to benefit from chemotherapy drugs such as cytosine arabinoside and daunorubicin. This novel approach has potential to improve the clinical management of patients with AML following validation in clinical trials.